Top

Cancer Chemotherapy and Pharmacology

Published in:

01-08-2013 | Original Article

Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer

Authors: Maged Mansour, Cynthia Mourad

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2013

Abstract

Purpose

Previous studies indicated that oral chemotherapy is convenient and preferred by many patients. We hereby report the efficacy and safety of oral vinorelbine as first-line chemotherapy for metastatic breast cancer (MBC).

Methods

Thirty-one patients with HER-2 negative MBC were enrolled between January 2007 and December 2010 in a prospective phase II trial. Patients were treated every 3 weeks with oral vinorelbine 60 mg/m² Days 1 and 8 for the 1st cycle and thereafter 80 mg/m² Days 1 and 8 every 3 weeks. Treatment was administered until disease progression or unexpected adverse event or patient refusal to continue. Primary endpoint was objective response rate (ORR); secondary endpoints were time-to-progression (TTP), overall survival (OS) and safety. Follow-up results until October 2012 are reported.

Results

Median age was 42 years (range 33–75). 26 (84 %) patients had 2 or more metastatic sites. A median of 6 cycles were administered (range 2–20). ORR was achieved in 9 (29 %) patients including 1 complete and 8 partial responses. 12 (39 %) patients had stable disease, resulting in a disease control rate of 68 %. Median TTP was 5.2 months [95 % CI 2.8–7.5]. Median OS was 16 months [95 % CI 11.3–20.7]. 3 (10 %) patients developed Grade 3–4 neutropenia. No events of febrile neutropenia, cardiac, renal toxicities or alopecia were recorded. Grade 3 thrombocytopenia and nausea-vomiting were reported in 2 (6 %) and 5 (16 %) patients, respectively.

Conclusion

Results show a good efficacy and tolerance profile of oral vinorelbine as first-line chemotherapy for HER-2 negative MBC patients.

O’Neill VJ, Twelves CJ (2002) Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 87(9):933–937. doi:10.1038/sj.bjc.6600591 PubMedCrossRef

Findlay M, von Minckwitz G, Wardley A (2008) Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 19(2):212–222. doi:10.1093/annonc/mdm285 PubMedCrossRef

Liu G, Franssen E, Fitch MI, Warner E (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115PubMed

Kuppens IE, Breedveld P, Beijnen JH, Schellens JH (2005) Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application. Cancer Invest 23(5):443–464PubMedCrossRef

Banna GL, Collova E, Gebbia V, Lipari H, Giuffrida P, Cavallaro S, Condorelli R, Buscarino C, Tralongo P, Ferrau F (2010) Anticancer oral therapy: emerging related issues. Cancer Treat Rev 36(8):595–605. doi:10.1016/j.ctrv.2010.04.005 PubMedCrossRef

Aapro MS, Conte P, Esteban Gonzalez E, Trillet-Lenoir V (2007) Oral vinorelbine: role in the management of metastatic breast cancer. Drugs 67(5):657–667PubMedCrossRef

Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P (2002) Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 38(3):349–358PubMedCrossRef

Catania C, Didier F, Leon ME, Sbanotto A, Mariani L, Nole F, Leida E, Rocca A, De Pas T, Goldhirsch A (2005) Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 92(3):265–272. doi:10.1007/s10549-005-3376-y PubMedCrossRef

Aisner J (2007) Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 64(9 Suppl 5):S4–S7. doi:10.2146/ajhp070035 PubMedCrossRef

10.

Parkin DM, Bray F, Ferlay J (2002) Pisani P (2005) Global cancer statistics. CA Cancer J Clin 55(2):74–108CrossRef

11.

O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29. doi:10.1634/theoncologist.10-90003-20 PubMedCrossRef

12.

Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN (2001) Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6(2):133–146PubMedCrossRef

13.

Jones SE (2008) Metastatic breast cancer: the treatment challenge. Clin Breast Cancer 8(3):224–233. doi:10.3816/CBC.2008.n.025 PubMedCrossRef

14.

Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20–37. doi:10.1634/theoncologist.12-1-20 PubMedCrossRef

15.

Comen EA, Fornier MN (2010) Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines. Clin Breast Cancer 10(Suppl 2):S7–19. doi:10.3816/CBC.2010.s.008 PubMedCrossRef

16.

Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Kostler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H (2007) Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 18(2):215–225. doi:10.1093/annonc/mdl155 PubMedCrossRef

17.

Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104(8):1742–1750. doi:10.1002/cncr.21359 PubMedCrossRef

18.

Chia SK, Speers CH, D’Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O’Reilly SE, Olivotto IA (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5):973–979. doi:10.1002/cncr.22867 PubMedCrossRef

19.

Stockler M, Wilcken NR, Ghersi D, Simes RJ (2000) Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 26(3):151–168. doi:10.1053/ctrv.1999.0161 PubMedCrossRef

20.

Kiely BE, Soon YY, Tattersall MH, Stockler MR (2011) How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29(4):456–463. doi:10.1200/JCO.2010.30.2174 PubMedCrossRef

21.

Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2:CD003372. doi:10.1002/14651858.CD003372.pub3 PubMed

22.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer (2012). Version 3

23.

Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii11–vii19. doi:10.1093/annonc/mds232 PubMedCrossRef

24.

Strada MR, Palumbo R, Bernardo A, Riccardi A, Teragni C, Poggi G, Frascaroli M, Amatu A, Montagna B, Sottotetti F, Tagliaferri B, Bernardo G (2012) Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials. Clin Breast Cancer 12(1):30–39. doi:10.1016/j.clbc.2011.11.001 PubMedCrossRef

25.

Gampenrieder SP, Bartsch R, Matzneller P, Pluschnig U, Dubsky P, Gnant MX, Zielinski CC, Steger GG (2010) Capecitabine and Vinorelbine as an All-Oral Chemotherapy in HER2-Negative Locally Advanced and Metastatic Breast Cancer. Breast Care (Basel) 5(3):158–162CrossRef

26.

Martin M, Ruiz A, Munoz M, Balil A, Garcia-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, Garcia-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodriguez CA, Adrover E, Mel JR (2007) Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 8(3):219–225. doi:10.1016/S1470-2045(07)70041-4 PubMedCrossRef

27.

Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M (2008) Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. Breast 17(2):180–185. doi:10.1016/j.breast.2007.09.002 PubMedCrossRef

28.

Freyer G, Delozier T, Lichinister M, Gedouin D, Bougnoux P, His P, Imadalou K, Trillet-Lenoir V (2003) Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 21(1):35–40. doi:10.1200/jco.2003.09.057 PubMed

29.

Blancas I, Morales S, Diaz N, Barnadas A, Gonzalvez ML, del Barco S, Lopez de Ceballos MH, Perez FJ, Llombart- Cussac A (2010) Efficacy and safety of oral vinorelbine in first or second-line metastatic breast cancer. J Clin Oncol 28 (15 s)

30.

Amadori D, Koralewski P, Tekiela A, Ruiz Simon A, Llombart Cussac A, Sommer H, Schindlbeck C, Maheut K, Lafaye de Micheaux S (2001) Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer (MBC). Eur J Cancer 27(Suppl 6):195CrossRef

31.

Ibrahim EM, al-Mulhim FA, al-Amri A, al-Muhanna FA, Ezzat AA, Stuart RK, Ajarim D (1998) Breast cancer in the eastern province of Saudi Arabia. Med Oncol 15(4):241–247PubMedCrossRef

32.

Ezzat AA, Ibrahim EM, Raja MA, Al-Sobhi S, Rostom A, Stuart RK (1999) Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncol 16(2):95–103PubMedCrossRef

33.

Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232–1239. doi:10.1093/jnci/djm086 PubMedCrossRef

34.

Palomo AG, Glogowska I, Sommer H, Malamos N, Kilar E, Vega JM, Torrecillas L, Delozier T, Ettl J, Finek J (2012) Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy. Anticancer Res 32(10):4539–4545PubMed

35.

Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS (2011) Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 29(34):4498–4504. doi:10.1200/JCO.2010.33.9101 PubMedCrossRef

36.

Blum JL, Barrios CH, Feldman N, Verma S, McKenna EF, Lee LF, Scotto N, Gralow J (2012) Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer. Breast Cancer Res Treat 136(3):777–788. doi:10.1007/s10549-012-2288-x PubMedCrossRef

Title: Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer
Authors: Maged Mansour
Cynthia Mourad
Publication date: 01-08-2013
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2216-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2013

Validation of tumour models for use in anticancer nanomedicine evaluation: the EPR effect and cathepsin B-mediated drug release rate

Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer

Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study

Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis

Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments

Keynote webinar | Spotlight on antibody–drug conjugates in cancer